Objective: It was our aim to compare the INNO-LiPA HPV Genotyping Extra (LiPA; Innogenetics) versus the Linear Array test (LA; Roche) in cervical samples. Study Design: One hundred cervical samples were selected, obtained from a cancer prevention center. All samples were human papillomavirus (HPV) DNA positive by Hybrid Capture 2 HPV test and genotyped by LA HPV genotyping test. All data were analyzed using Cohen’s ĸ tests. ĸ values ranged from poor, fair, moderate and good to very good agreement strength. Results: Detection of multiple infection and HPV genotypes per sample was higher by LA than by LiPA (61.5 vs. 52.1 and 2.2 vs. 1.7%, respectively). There were concordant results in 65 samples and compatible results in 33 samples. Only 2 samples were considered as discordant. In 21 samples, additional types were detected by LA, and in 13 samples, additional types were detected by LiPA. Analyzing the ĸ values, we have found very good agreement for 14 genotypes (6, 16, 26, 31, 33, 35, 45, 51, 52, 53, 58, 66, 68 and 70). Conclusions: We considered that the new LiPA is highly comparable with other methods and suitable for clinical and epidemiological studies.

Keywords:
Human papillomavirus, Reverse hybridization, Human papillomavirus genotyping, Linear arrays, INNO-LiPA Extra
1.
Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV: The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244–265.
2.
van Hamont D, Bekkers RL, Massuger LF, Melchers WJ: Detection, management, and follow-up of pre-malignant cervical lesions and the role for human papillomavirus. Rev Med Virol 2008;18:117–132.
3.
Meijer CJ, Snijders PJ, Castle PE: Clinical utility of HPV genotyping. Gynecol Oncol 2006;103:12–17.
4.
Kleter B, van Doorn LJ, Schrauwen L, Molijn A, Sastrowijoto S, ter Schegget J, et al: Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 1999;37:2508–2517.
5.
van Doorn LJ, Quint W, Kleter B, Molijn A, Colau B, Martin MT, et al: Genotyping of human papillomavirus in liquid cytology cervical specimens by the PGMY line blot assay and the SPF(10) line probe assay. J Clin Microbiol 2002;40:979–983.
6.
Sabol I, Salakova M, Smahelova J, Pawlita M, Schmitt M, Gasperov NM, et al: Evaluation of different techniques for identification of human papillomavirus types of low prevalence. J Clin Microbiol 2008;46:1606–1613.
7.
Klug SJ, Molijn A, Schopp B, Holz B, Iftner A, Quint W, et al: Comparison of the performance of different HPV genotyping methods for detecting genital HPV types. J Med Virol 2008;80:1264–1274.
8.
Fontaine V, Mascaux C, Weyn C, Bernis A, Celio N, Lefevre P, et al: Evaluation of combined general primer-mediated PCR sequencing and type-specific PCR strategies for determination of human papillomavirus genotypes in cervical cell specimens. J Clin Microbiol 2007;45:928–934.
9.
van Hamont D, van Ham MA, Bakkers JM, Massuger LF, Melchers WJ: Evaluation of the SPF10-INNO LiPA human papillomavirus (HPV) genotyping test and the Roche linear array HPV genotyping test. J Clin Microbiol 2006;44:3122–3129.
10.
Monsonego J, Pollini G, Evrard MJ, Sednaoui P, Monfort L, Zerat L, et al: Detection of human papillomavirus genotypes among high-risk women: a comparison of hybrid capture and linear array tests. Sex Transm Dis 2008;35:521–527.
11.
Monsonego J, Pollini G, Evrard MJ, Sednaoui P, Monfort L, Quinzat D, et al: Linear array genotyping and hybrid capture II assay in detecting human papillomavirus genotypes in women referred for colposcopy due to abnormal Papanicolaou smear. Int J STD AIDS 2008;19:385–392.
12.
Dockter J, Schroder A, Hill C, Guzenski L, Monsonego J, Giachetti C: Clinical performance of the APTIMA HPV Assay for the detection of high-risk HPV and high-grade cervical lesions. J Clin Virol 2009;45(suppl 1):S55–S61.
13.
Poljak M, Marin IJ, Seme K, Vince A: Hybrid Capture II HPV Test detects at least 15 human papillomavirus genotypes not included in its current high-risk probe cocktail. J Clin Virol 2002;25(suppl 3):S89–S97.
14.
Safaeian M, Herrero R, Hildesheim A, Quint W, Freer E, Van Doorn LJ, et al: Comparison of the SPF10-LiPA system to the Hybrid Capture 2 Assay for detection of carcinogenic human papillomavirus genotypes among 5683 young women in Guanacaste, Costa Rica. J Clin Microbiol 2007;45:1447–1454.
15.
Maver PJ, Kocjan BJ, Seme K, Potočnik M, Gale N, Poljak M: Prevaccination genomic diversity of human papillomavirus genotype 11: a study on 63 clinical isolates and 10 full-length genome sequences. J Med Virol 2011;83:461–470.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.